Histogen (FRA:CPH) Insider Ownership : 0.00 % (As of Jun. 14, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Histogen Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Histogen's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Histogen's Institutional Ownership is 0.46%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Histogen's Float Percentage Of Total Shares Outstanding is 97.07%.

Histogen Insider Ownership Historical Data

The historical data trend for Histogen's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen Insider Ownership Chart

Histogen Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Insider Ownership

Histogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Insider Ownership	Get a 7-Day Free Trial													-	-	-	-	-

Histogen Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Histogen (FRA:CPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (FRA:CPH) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

HSTO:USA

Address

10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.histogen.com

Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Histogen (FRA:CPH) Headlines

No Headlines